This article outlines the issue of polypharmacy among older adults and their increased risk for adverse drug reactions. The article describes:

  • Age-related changes,
  • The lack of evidence for medication use in the elderly, and
  • Strategies for reducing polypharmacy.

The Research for Aging Institute (RIA), a collaborative between The Univerity of Waterloo, Conestoga College, and Schlegel Villages include Optimizing Medications for Seniors as a theme for their research and education. Visit their website for a complete list of research projects.

It has been reported that up to one-quarter of patients who visit emergency departments (ED) due to adverse drug reactions (ADRs) are admitted to hospital. ADRs resulting in hospital admission generally represent more severe reactions and require more resources to treat. One recent study found that ED visits and hospital admissions due to ADRs among seniors in Canada cost an estimated $35.7 million, with more than 80% of those costs arising from hospitalization. 

The National Institutes on Deafness and Other Communication Disorders has an action plan aimed at deaf/hard of hearing students contemplating research as a career, and deaf/hard of hearing scientists or other scientists wishing to serve as mentors for research training and career development of deaf/hard of hearing students.

This article will review the literature on visual spatial cognition in neurodegenerative disease clinical syndromes, and where research is available, by neuropathologic diagnoses. Visual spatial cognition will be organized primarily according to the following schemes: bottom-up/top-down processing, dorsal / ventral stream processing, and egocentric / allocentric frames of reference

International Federation on Aging’s report highlights the critical need for action and investment in preventive eye health. By focusing on prevention and early detection of visual impairments, we are promoting a more active and productive older population, which can drive economic activity and mitigate costs of care and other financial burdens associated with ageing and chronic diseases. Across the globe, new policies to improve the diagnosis, management, and care associated with preventable eye diseases – especially among ageing populations – will go a long way in alleviating the burdens triggered by age-related vision loss.

Visual impairment and blindness are common in older people in Britain. It is important to know the causes of visual impairment to develop health service and research priorities. The authors aimed to identify the causes of visual impairment in people aged 75 years and older in Britain.

This web page outlines the national plan for eye and vision research pertaining to low vision and blindness rehabilitation at the National Eye Institute. it provides background information on low vision and blindness rehabilition, program goals, highlights of revent progress, and their program objectives.

Age related macular degeneration (AMD) accounts for almost 50% of those registered as blind or partially sighted. 1-4 The development of management strategies is limited by the diverse nature of the age related changes and a lack of a clear understanding of the process of visual loss in the elderly. Effective treatment is limited to the management of sub-retinal neovascularisation (SRNV) in selected cases). Despite early expectations that laser treatment might provide significant benefit in preventing blindness 5-7 recurrent disease and progressive visual failure limit the final outcome. 8-9. Early recognition and prevention of potential disease is not as yet applicable to disease other than that related to SRNV. 

Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for “straight-ahead” activities such as reading, sewing, and driving. AMD affects the macula, the part of the eye that allows you to see fine detail. AMD causes no pain.